Personalizing Patient Management and Oral Adherence for the Oncology Patient

ASHP 2016 - ASHP 2016 - Oncology, Conference Correspondent

In a product theater presentation, Jacob K. Kettle, PharmD, BCOP, of the University of Missouri Health Care-Ellis Fischel Cancer Center, provided an overview of the importance of medication therapy management (MTM) for oncology patients as the number of approved oral oncology therapies rise, and highlighted the role oncology pharmacists can play at their respective institutions.

Kettle states that new oral oncolytics are hitting the market 12 times faster than prior to 2003, as reported by Mancini and colleagues, and about 50 oral oncolytics are currently on the market.1 Many oncology patients today have multiple comorbidities that lead to polypharmacy and with chemotherapy regimens and treatment schedules becoming more and more complex, there is an increased need for MTM. The increased use of oral oncolytics has highlighted the incidence of different side effects, such as cardiac stomatitis and pulmonary effusions, which many pharmacists still need time to understand and manage.

MTM in oncology provides an opportunity for many oncology pharmacists to monitor oral adherence and overcome the barriers related to oral oncolytics. Kettle recommends that by pharmacists identifying and resolving drug-related problems through MTM, it helps to promote healthcare provider collaboration and encourages pharmacists to move from a dispensing ideology to focus more on the patient and less on the product. Ramalho de Oliveira and colleagues reported that MTM improves patient outcomes. Their study showed an improvement in 55% of patients’ medical conditions and 95% of patients felt that their overall health and well-being improved through MTM therapy.2

An MTM program traditionally includes 5 components: medication therapy review, personal medication record, medication action plan, intervention and referral, and documentation and follow-up. Kettle also stressed the importance of highlighting the financial concerns of patients and how they are often missed in patient consultations.

Overall, MTM in oncology is very important as the rise of oral oncolytics continues. It helps promote adherence and can ultimately increase patient education and improve patient outcomes. Kettle closed by emphasizing, “People don’t care what you know, until they know that you care.”

Kettle JK. Product theater presentation at ASHP Midyear Clinical Meeting. Las Vegas, NV; December 2016.

  1. Mancini R, McBride A, Kruczynski M. Oncology (Williston Park). 2013;27(8):742-744, 824.
  2. Ramalho de Oliveira D, Brummel AR, Miller DB. J Manag Care Pharm. 2010;16(3):185-195.
Related Items
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Multiple Myeloma
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates & News, ASH
“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, AONN+
Silent Patients Find Their Voices Through an Advocate’s Journey
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Patient Advocacy, Conference Correspondent, ESMO
Measuring Financial Well-Being in Cancer Survivorship
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Survivorship
Combining Immunotherapy and Radiotherapy Shows Good Synergy
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Immunotherapy, Conference Correspondent
Quizartinib Combinations Show High Activity in Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates & News
Humanizing Cancer Care: The Patient Perspective
Gail Thompson
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ACCC
Emerging Safety Data with Checkpoint Inhibitors
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Last modified: December 13, 2016